Liraglutide Explored for Cognitive Dysfunction in Mood Disorders
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
Background
Bipolar Disorder and Major Depressive Disorder are often accompanied by significant cognitive dysfunction, impacting daily life and treatment outcomes. While glucagon-like peptide-1 (GLP-1) agonists like liraglutide are primarily known for treating type 2 diabetes and obesity, emerging evidence suggests they may have neuroprotective and cognitive-enhancing effects. This Phase 3 clinical trial aimed to investigate the potential cognitive benefits of adjunctive liraglutide in patients with mood disorders.
Study Design
Population
Patients with Bipolar Disorder and Major Depressive Disorder experiencing cognitive dysfunction.
Intervention
Adjunctive liraglutide.
Outcome
Potential cognitive benefits.
